Pear Therapeutics to Become Public Via THMA SPAC Merger for ~$1.6B

 Pear Therapeutics to Become Public Via THMA SPAC Merger for ~$1.6B

Pear Therapeutics to Become Public Via THMA SPAC Merger for ~$1.6B

Shots:

  • Pear signs a SPAC merger with THMA for pro forma equity value of ~ $1.6B & is expected to provide ~ $400M in gross proceeds include $276M in Thimble Point’s trust account & $125M upsized PIPE at $10.00/ share. The combined company is expected to have ~$450M in net cash & transaction is expected to end in H2’21
  • The combination will provide additional investment to capitalize Pear’s leading position by investing in the commercialization of Pear’s 3 FDA-authorized products, advance Pear’s pipeline & scaling its platform to host PDTs
  • Pear equity holders will hold ~72% outstanding equity of combined company while Pear expect to be trade on Nasdaq under the ticker “PEAR”

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post